5-Amino-1MQ: A Research Overview of the NNMT Inhibitor

5-Amino-1MQ sits a little apart from the peptides it is often grouped with online. It is not a peptide at all — it is a small molecule, an enzyme inhibitor — and that single distinction shapes both its mechanism and its regulatory standing. It attracts research attention because it targets a metabolic pathway that few other compounds affect, making it a useful tool for asking questions rather than a proven answer to any of them.

This overview summarizes the published literature on what 5-Amino-1MQ is, how it is proposed to work, the shape of its evidence base, and its current regulatory status. Throughout, it describes what studies observed in their experimental systems. It is not dosing guidance, medical advice, or a recommendation for use.

What 5-Amino-1MQ Is

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule, membrane-permeable inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It is worth correcting a common error up front: despite frequently appearing on peptide vendor sites, it is not a peptide — it has no amino-acid chain. It emerged from structure-activity work at the University of Texas, described in a 2017–2018 series of studies as a tool compound capable of entering cells efficiently, which earlier NNMT inhibitors could not (NNMT inhibitor development overview). That cell permeability is precisely why it became the standard probe for studying NNMT inside living cells.

Proposed Mechanism

The mechanism is best understood through the enzyme it blocks. NNMT methylates nicotinamide, consuming a methyl group from S-adenosylmethionine (SAM) in the process. Researchers describe this as a “methyl sink”: when NNMT is highly active, it draws down both nicotinamide — a precursor in the NAD+ salvage pathway — and SAM, the cell’s main methyl donor. A notable observation that motivated the field is that NNMT activity is markedly elevated in the fat tissue of obese animals (NNMT and metabolic syndrome review, Frontiers).

By inhibiting NNMT, 5-Amino-1MQ is proposed to relieve that sink — in cell and animal studies, it is associated with increases in NAD+ and SAM, and downstream with a metabolic shift in adipocytes toward fat oxidation rather than storage. The proposed signaling chain, often summarized in the literature, runs from NNMT inhibition to elevated NAD+ levels to activation of sirtuins and PGC-1α, and ultimately to increased energy expenditure. That cascade is mechanistically coherent and is the reason the compound is studied — but it is a model derived from preclinical systems, not a demonstrated effect in people.

The Evidence Base — Strongly Preclinical

Of the compounds in this research library, 5-Amino-1MQ has one of the most clearly preclinical evidence profiles, and being precise about that is the whole point of an honest overview.

The defining study was published by Neelakantan and colleagues in Biochemical Pharmacology in 2018. The investigators administered 5-Amino-1MQ to diet-induced obese mice and reported significantly reduced body weight and white adipose tissue mass, smaller adipocytes, and lowered plasma cholesterol — notably, without any change in food intake, a result the authors interpreted as enhanced lipid oxidation rather than appetite suppression (Neelakantan et al., 2018, summarized with study specifics). This was built on earlier genetic work (Kraus and colleagues, 2014) that knocked down NNMT in rodents and pointed in the same direction.

Subsequent preclinical work has extended NNMT inhibition into muscle and aging contexts, including studies linking it to stem-cell activation and muscle regeneration in aged animal models (muscle and NAD+ research summary). What is consistently missing, however, is human efficacy data. As one summary of the field put it, no human trials have established efficacy, even though some clinics have begun offering the compound ahead of that evidence — a gap between practice and proof that is itself worth noting (NNMT in obesity & T2D (review, PMC)).

• The findings described here come from cell culture and rodent studies, not from completed human clinical trials.
• The pivotal obesity result was a short study (about 11 days) in mice; long-term effects and reversibility in humans are unknown.
• Mouse-to-human dose extrapolations circulating online are estimates based on allometric scaling, not validated human doses.

Regulatory Status

Status below reflects mid-2026 and may change; verify against current sources before relying on it. 5-Amino-1MQ is not approved by the FDA for any use in humans. It has not been evaluated by the agency for safety or efficacy, and it cannot lawfully be marketed as a drug or as a dietary supplement (NNMT inhibitor research context (review, PMC)).

Its regulatory position differs from that of the research peptides it is often listed alongside, and the difference is instructive. Because 5-Amino-1MQ is a small molecule rather than a peptide, it is not part of the FDA’s 503A peptide-compounding discussions at all — it is not on the 503A bulk drug substances list and has no compounding-pharmacy access pathway. It is instead described as a research compound that would need to undergo the conventional drug-development process to obtain approval (NNMT inhibitor research context (review, PMC)). In practical terms, that means there is no legitimate clinical or compounded route to it in U.S. practice as of this writing; material encountered outside a formal research setting is a research-grade chemical sold for laboratory use only.

Why 5-Amino-1MQ Draws Research Interest

The interest is genuine and specific. 5-Amino-1MQ targets a metabolic checkpoint — the NNMT-controlled junction of NAD+ salvage and methylation — that sits outside the pathways hit by appetite suppressants, mitochondrial uncouplers, or exercise mimetics. For metabolic researchers, a selective, cell-permeable probe for that node is a valuable tool, and the consistent preclinical signal across obesity and muscle models keeps the questions alive. The honest framing is that it is mechanistically novel and preclinically promising, but clinically unproven and not yet approved by regulators — an interesting research compound, not a finished therapy.

For deeper reading, the primary literature cited throughout this article is the best starting point. Related metabolic-pathway and NAD+-biology topics are collected in our peptide research library, which gathers reference material on the wider class of compounds discussed here.